About
Hexagon Nutrition Limited is a research-oriented nutrition company engaged in the development, manufacturing, and marketing of a wide range of nutrition products. The company operates across the nutrition value chain, offering micronutrient premixes, therapeutic and clinical nutrition products, and solutions for food fortification and malnutrition. It provides customised vitamin and mineral premixes to domestic and international fast-moving consumer goods companies and also supplies micronutrient powders for public health programmes. Its product portfolio addresses various nutritional needs, including clinical nutrition and preventive healthcare. The company follows an integrated business model, with capabilities spanning research and development, production, and distribution, and focuses on quality-driven offerings. Revenue is primarily generated through the sale of these nutrition products across different customer segments, including institutional and commercial clients.
IPO schedule
| Issue open date | 2026-06-05 |
| Issue close date | 2026-06-09 |
| UPI mandate deadline | 2026-06-09 (5 PM) |
| Allotment finalization | 2026-06-10 |
| Refund initiation | 2026-06-11 |
| Share credit | 2026-06-11 |
| Listing date | 2026-06-12 |
| Mandate end date | 2026-06-24 |
| Lock-in end date for anchor investors (50%) | 2026-07-09 |
| Lock-in end date for anchor investors (remaining) | 2026-09-07 |
Financials
| Financial Year Ended | March 2024 | March 2025 | December 2025 |
| Total Assets | 250.54 | 261.36 | 327.6 |
| Revenue | 304.62 | 331.29 | 275.57 |
| Profit After Tax | 12.21 | 24.38 | 27.03 |
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 138.87 |
| Offer for sale - Proceeds go to the existing investors | 138.87 |
Strengths
- Integrated nutrition company with capabilities from R&D to manufacturing and marketing.
- Diverse product portfolio covering premixes, clinical, and therapeutic nutrition.
- Strong presence in micronutrient premixes for FMCG companies.
- Supplier to global public health programmes for micronutrient powders.
- Focus on research-driven and quality-oriented product development.
Risks
- Heavy dependence on the premix formulation segment for revenue.
- High revenue concentration from a limited number of customers.
- Exposure to raw material price volatility due to a lack of long-term contracts.
- Risk of product quality issues leading to liability and reputational damage.
- Dependence on successful R&D and new product commercialisation.
Allotment Status for Hexagon Nutrition
To check your IPO allotment status:
- Visit the Kfin Technologies IPO Application Status page.
- Select the company name from the dropdown menu.
- Select and enter one of the following: PAN, Application Number, DP/Client ID, or Account Number/IFSC.
- Click Submit to view your allotment status.